Section 1: Introduction -- The Disease of Caribbean Men

A 54-year-old man in Georgetown, Guyana presents with his third gout attack in eight months. His great toe is swollen, red, and exquisitely tender. His serum urate is 620 µmol/L. His clinician prescribes indomethacin for the attack and, at the same visit, starts allopurinol 300 mg daily because "the uric acid is too high."

Three days later, the patient calls to say his gout is significantly worse. He stops the allopurinol, believing it has caused a reaction.

It has not caused a reaction. Starting allopurinol during an acute attack -- or in the period immediately after -- mobilises urate crystals from existing deposits and precipitates further attacks. This is documented, predictable, and extremely common in Caribbean practice. The correct time to start allopurinol is when the acute attack has completely resolved, under cover of prophylactic colchicine.

Gout has a distinctive Caribbean epidemiological profile. It is common, driven by diet and by the high rates of hypertension and diuretic use in the region, frequently undertreated, and associated with specific drug interactions -- one of which (allopurinol and azathioprine) is potentially fatal if not recognised.

Caribbean gout prescribing has five specific challenges:

Starting urate-lowering therapy at the wrong time. Allopurinol started during or immediately after an acute attack provokes further attacks and is frequently abandoned by the patient, who never restarts it.

Undertreating acute attacks. NSAIDs are withheld in patients with renal impairment or peptic ulcer disease without offering an effective alternative. Colchicine doses are sometimes excessive. Corticosteroids are underused in patients where both NSAIDs and colchicine are contraindicated.

The allopurinol-azathioprine interaction. Azathioprine (used for inflammatory bowel disease, rheumatoid arthritis, renal transplant, and lupus) is metabolised by xanthine oxidase -- the same enzyme that allopurinol inhibits. Co-prescription causes azathioprine levels to rise to potentially fatal levels. This is among the most dangerous drug interactions in routine clinical use.

Dietary triggers in the Caribbean context. Red meat, organ meats, seafood, alcohol (particularly beer and spirits), and high-fructose drinks all raise serum urate. These are common dietary elements in many Caribbean communities. Dietary advice must be culturally contextualised, not copied from guidance designed for other populations.

Diuretics and urate. Thiazide and loop diuretics -- the most widely used antihypertensives and diuretics in the Caribbean -- raise serum urate by reducing renal urate excretion. Many Caribbean men with gout are on a diuretic for their hypertension. Reviewing whether the diuretic is essential, or can be switched to a urate-neutral or urate-lowering antihypertensive (losartan, amlodipine), is part of gout management.

Section 2: Acute Gout -- Diagnosing and Treating the Attack

2.1 Diagnosis

Gout is caused by deposition of monosodium urate crystals in joints, tendons, and surrounding tissues. The classic presentation is acute monoarthritis -- typically the first metatarsophalangeal joint (podagra), but also the ankle, knee, wrist, and small joints of the hand.

Diagnostic features: - Acute onset, typically overnight or on waking - Maximum intensity within 12-24 hours - Exquisite tenderness -- often the joint cannot tolerate the weight of a bedsheet - Erythema, warmth, and swelling of the affected joint - Spontaneous resolution within 7-14 days without treatment - History of prior attacks, frequently in the same joint

Serum urate: Elevated serum urate (above 360 µmol/L in men, above 300 µmol/L in women) supports the diagnosis but is not diagnostic -- serum urate may be normal during an acute attack (the acute phase response redistributes urate). A normal serum urate does not exclude gout.

Joint aspiration demonstrating negatively birefringent, needle-shaped monosodium urate crystals under polarised light microscopy is the diagnostic gold standard. Where aspiration is not available, the clinical diagnosis is sufficient to guide management.

2.2 Acute attack treatment

Treatment should start as soon as possible -- within the first 12-24 hours. Delayed treatment extends the duration and severity of the attack.

Three options, in order of evidence:

Colchicine: The preferred first-line treatment for acute gout in most patients. Anti-inflammatory through inhibition of tubulin polymerisation and neutrophil activation.

Dosing: 1 mg immediately, then 0.5 mg one hour later (total 1.5 mg in the first day). Then 0.5 mg twice or three times daily for 7-10 days until attack resolves. This low-dose regimen is as effective as the traditional high-dose regimen and substantially less toxic.

The traditional high-dose colchicine regimen (0.5 mg every 2 hours until relief or GI toxicity) is no longer recommended. It causes diarrhoea, nausea, and vomiting in the majority of patients and has caused fatal overdoses.

Contraindications: severe renal impairment (CrCl below 10), severe hepatic impairment, concurrent strong CYP3A4 or P-glycoprotein inhibitors (clarithromycin, ciclosporin -- accumulation causes colchicine toxicity). Dose reduce in moderate renal impairment.

NSAIDs (naproxen, indomethacin, diclofenac): Effective for acute gout but carry the usual NSAID risks -- GI bleeding, renal impairment, cardiovascular risk (Report 7). Avoid in CKD, peptic ulcer disease, cardiac failure, and in the elderly. Naproxen 500 mg twice daily or indomethacin 50 mg three times daily for 5-7 days.

Corticosteroids (prednisolone, oral or IM triamcinolone): The most appropriate option when both colchicine and NSAIDs are contraindicated (CKD, peptic ulcer, anticoagulation). Prednisolone 30-35 mg/day for 5 days is effective and well-tolerated for short courses. Can be administered as a single intramuscular injection of triamcinolone 40 mg where rapid response is needed.

Monitor glucose in diabetic patients during corticosteroid courses (Report 4, Report 8).

Section 3: Urate-Lowering Therapy -- Starting It Right

3.1 Indications for allopurinol

Not every patient who has had a gout attack requires urate-lowering therapy. Indications: - Two or more gout attacks per year - Tophi (subcutaneous urate deposits) - Gout with CKD (urate is nephrotoxic) - Gout with urolithiasis - Radiographic joint damage from gout - Serum urate persistently above 480 µmol/L with any history of gout

3.2 The timing rule -- never during or immediately after an attack

Starting allopurinol during an acute attack or within 2-4 weeks of resolution mobilises urate from existing deposits, precipitating further acute attacks. This is a pharmacologically predictable consequence of rapid serum urate lowering in a patient with pre-existing urate crystal deposits.

The correct protocol: 1. Treat the acute attack to complete resolution 2. Wait at least 2-4 weeks after complete resolution 3. Start allopurinol at a low dose (50-100 mg/day) 4. Cover with prophylactic colchicine 0.5 mg daily for the first 3-6 months of allopurinol treatment 5. Increase allopurinol dose every 2-4 weeks until serum urate target is achieved

3.3 Allopurinol dosing and the serum urate target

Serum urate target: Below 360 µmol/L (6 mg/dL). For patients with tophi or severe gout, below 300 µmol/L. Check serum urate every 2-4 weeks during dose titration.

Starting dose: 50-100 mg/day. This is lower than the traditional 300 mg starting dose specifically to reduce mobilisation-related flares.

Titration: Increase by 50-100 mg every 2-4 weeks until the urate target is achieved.

Maximum dose: 900 mg/day (UK guidelines); 800 mg/day (US guidelines).

Renal dosing: Allopurinol and its active metabolite (oxypurinol) are renally cleared. In CKD, clearance is reduced and dose must be adjusted:

The most important instruction to every patient on allopurinol: allopurinol does not treat acute attacks. It is a long-term preventive therapy. Gout attacks during early allopurinol treatment are expected and do not mean the drug is failing. Do not stop allopurinol during an attack -- stopping and restarting prolongs the mobilisation period and increases the frequency of attack flares.

Section 4: The Allopurinol-Azathioprine Interaction -- A Drug Interaction That Kills

Azathioprine is used for: - Inflammatory bowel disease (Crohn's disease, ulcerative colitis) - Rheumatoid arthritis - Renal transplant immunosuppression - Lupus nephritis - Other autoimmune conditions

Azathioprine is metabolised to its active form (6-thioguanine nucleotides) by a pathway that does not involve xanthine oxidase. However, azathioprine is also metabolised to inactive metabolites by xanthine oxidase -- this is a major detoxification pathway.

Allopurinol inhibits xanthine oxidase. When allopurinol is co-prescribed with azathioprine: - The detoxification pathway for azathioprine is blocked - Active metabolite accumulates - Severe, potentially fatal bone marrow suppression results -- leukopenia, thrombocytopenia, anaemia - The onset can be rapid or delayed

The interaction is dose-dependent. If allopurinol must be used in a patient on azathioprine (for example, where gout develops in a transplant patient who cannot stop azathioprine), the azathioprine dose must be reduced to 25% of the usual dose immediately and full blood count monitored weekly.

In all other cases, the combination should be avoided. If a patient on azathioprine develops gout requiring urate-lowering therapy, use febuxostat (a non-xanthine oxidase inhibitor) instead of allopurinol. If allopurinol is already prescribed and azathioprine is to be started, substitute allopurinol with febuxostat before starting azathioprine.

ElesRx flags this interaction as a contraindicated combination at the point of prescription.

Section 5: Drug Interactions and Gout Triggers

5.1 Drugs that raise serum urate

5.2 Losartan -- the urate-lowering antihypertensive

Losartan (an ARB) has a mild uricosuric effect -- it increases renal urate excretion. Among the antihypertensives, it is the preferred agent when a patient has both hypertension and gout. Switching from a thiazide diuretic to losartan in a patient with hypertension and gout provides antihypertensive benefit, reduces the thiazide-mediated urate rise, and provides a modest uricosuric effect.

5.3 Allopurinol and ampicillin / amoxicillin

Allopurinol combined with ampicillin or amoxicillin is associated with a significantly higher rate of skin rash (approximately 20% with the combination vs 2% with amoxicillin alone). The mechanism is not fully established. Where an antibiotic is needed in a patient on allopurinol, use an alternative (doxycycline, co-amoxiclav, or a macrolide) where clinically appropriate.

5.4 Colchicine drug interactions

Colchicine is a substrate of CYP3A4 and P-glycoprotein. Inhibitors of these cause colchicine accumulation:

Colchicine should be avoided or the dose reduced substantially in patients on these drugs.

Section 6: Diet and Lifestyle in the Caribbean Context

Dietary urate precursors -- purines -- are metabolised to uric acid in the body. High-purine foods raise serum urate. The following are particularly relevant in Caribbean dietary practice:

The clinical point: dietary modification alone rarely achieves the serum urate target in patients with established gout. Diet is important but is adjunctive to pharmacological urate-lowering therapy, not a substitute for it.

Section 7: Febuxostat -- The Allopurinol Alternative

Febuxostat is a non-purine, selective xanthine oxidase inhibitor. It does not inhibit other enzymes involved in purine and pyrimidine metabolism, making it more selective than allopurinol.

Advantages over allopurinol: - Does not cause the hypersensitivity reaction associated with allopurinol (allopurinol hypersensitivity syndrome, though rare, carries 20-25% mortality) - Can be used in mild-to-moderate CKD without dose adjustment (to CrCl above 30) - Does not interact with azathioprine through xanthine oxidase inhibition (though monitoring is still prudent) - No dose titration for renal impairment in mild-to-moderate CKD

Disadvantages: - More expensive than allopurinol - The CARES trial (2018) raised a cardiovascular safety signal -- higher cardiovascular mortality with febuxostat vs allopurinol in patients with established cardiovascular disease. The FDA added a boxed warning. Subsequent analysis suggested this was driven by non-adherence to allopurinol in the comparator arm. Febuxostat remains appropriate where allopurinol cannot be used, but patients with established CVD should be monitored.

Dosing: 80 mg daily; increase to 120 mg daily if serum urate target not achieved at 80 mg. No renal dose adjustment required down to CrCl 30 mL/min.

Section 8: The Gout Prescribing Checklist

Section 9: About ElesRx

ElesRx flags the allopurinol-azathioprine combination as a contraindicated interaction requiring immediate clinical review. The system also identifies concurrent thiazide or loop diuretics in patients on allopurinol and generates a urate-raising drug alert, flags colchicine interactions with clarithromycin and ciclosporin, and highlights allopurinol with aminopenicillins (rash risk).

The tool is available at elesrx.com. ElesRx is a product of PIPPS Smart Apps, a division of J.C. Epiphany Limited (Jamaica, est. 1998).

Section 10: Methodology and References

10.1 Data sources

Gout management data is drawn from the ElesRx clinical database, DailyMed, the European Alliance of Associations for Rheumatology (EULAR) gout guidelines (2020), the American College of Rheumatology gout guidelines (2020), and the European Medicines Agency.

10.2 Limitations

Management of severe tophaceous gout requiring surgical debridement, pegloticase infusion therapy for refractory gout, and specialist-level management of gout in transplant recipients are beyond this report's primary scope.

10.3 Author and conflict of interest disclosure

This report was authored by Juliet Duncan, BPharm, founder of J.C. Epiphany Limited and developer of ElesRx. The author has a commercial interest in ElesRx. This report is published without an access gate as a contribution to Caribbean clinical education. No external funding was received.

10.4 Citation

Duncan J. The Gout Report: Allopurinol, Acute Attacks, and the Drug Interaction That Can Be Fatal. ElesRx Clinical Reports, Report 23. Prepared June 2026. Published 2027 at elesrx.com/reports/gout-report/. J.C. Epiphany Limited, Jamaica.

References

1. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi:10.1136/annrheumdis-2016-209707

2. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res. 2020;72(6):744-760. doi:10.1002/acr.24180

3. White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout (CARES trial). N Engl J Med. 2018;378(13):1200-1210. doi:10.1056/NEJMoa1710895

4. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare. Arthritis Rheum. 2010;62(4):1060-1068. doi:10.1002/art.27327

5. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925-934. doi:10.4065/81.7.925